ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South...

Stay True to Our Original Aspiration, Forge Ahead into the Future|Alphamab Oncology 2025 R&D Day Successfully Held

Stay True to Our Original Aspiration, Forge Ahead into the Future|Alphamab Oncology 2025 R&D Day Successfully Held

SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on...

menu
menu